Podcasts about disease research

Overview This special episode of the Tick Boot Camp Podcast was recorded live at the 2nd Annual Alzheimer's Pathobiome Initiative (AlzPI) and PCOM Symposium in collaboration with Pathobiome Perspectives. Hosted by Ali Moresco in partnership with Nikki Schultek, Executive Director of AlzPI, the conversation brings the Tick Boot Camp mission of exploring infection-associated chronic illness (IACI), like Lyme disease and other tick-borne diseases, to the global Alzheimer's and neuroimmunology research community. Tick Boot Camp co-founders Matt Sabatello and Rich Johannesen partnered with Ali and Nikki to highlight scientists whose work connects tick-borne illness, microbes, and cognitive decline. This episode features Dr. Brian J. Balin, an internationally recognized neuroscientist whose research has redefined the role of infection in contributing to Alzheimer's disease. Guest Brian J. Balin, PhD Professor of Neuroscience and Neuropathology Director, Center for Chronic Disorders of Aging Philadelphia College of Osteopathic Medicine (PCOM) Dr. Balin directs the Center for Chronic Disorders of Aging and the Adolph and Rose Levis Foundation Laboratory for Alzheimer's Disease Research at PCOM. With a PhD from the University of Maryland School of Medicine and postdoctoral training at the University of Pennsylvania, he has devoted nearly three decades to understanding how chronic infection and inflammation trigger neurodegeneration. His pioneering discovery that the respiratory bacterium Chlamydia pneumoniae infects brain tissue helped establish the Pathogen Hypothesis of Alzheimer's disease. His continuing work explores how tick-borne microbes — including Borrelia burgdorferi (Lyme disease), Bartonella, and Babesia — interact with other pathogens to drive neuroinflammation and cognitive decline. Key Discussion Points How infections such as Chlamydia pneumoniae, Borrelia burgdorferi, Bartonella, and Babesia were detected in Alzheimer's brain tissue. Evidence that microbes can enter the brain via the olfactory pathway or blood-brain barrier, initiating chronic inflammation, amyloid plaque formation, and tau tangle pathology. Findings from Dr. Balin's collaboration with Galaxy Diagnostics and advocate Nicole Bell, revealing polymicrobial infection and even Babesia otocoli — a strain previously believed to infect only deer — in human brain tissue. The use of animal models and 3D human brain organoids to study infection-driven neurodegeneration. Why identifying infection as part of the exposome (environmental insults over a lifetime) is key to developing precision diagnostics and treatments. Future directions: immune-modulating drugs, antimicrobials, and emerging phage therapy. “Infection is part of the exposome — an environmental insult that shapes our health over a lifetime. Recognizing that is key to truly understanding and preventing Alzheimer's disease.” — Dr. Brian J. Balin Why It Matters Dr. Balin's research bridges the worlds of neurology and infectious disease, offering a framework that could revolutionize how Alzheimer's and other neurodegenerative conditions are diagnosed and treated. By recognizing that microbes — including those transmitted by ticks — can initiate neuroinflammation and cognitive decline, his work provides hope for millions living with infection-associated chronic illness. About the Event The interview took place at the 2nd Annual Alzheimer's Pathobiome Initiative (AlzPI) and Philadelphia College of Osteopathic Medicine (PCOM) Symposium, October 3, 2025, Ohio University in Dublin, Ohio. The Symposium brought together more than 20 experts exploring how microbes, the microbiome, and the host immune response contribute to neurological and psychiatric diseases such as Alzheimer's, dementia, and PANS/PANDAS. Tick Boot Camp partnered with Ali Moresco and Nikki Schultek to document and share the voices of scientists advancing research on infection-associated chronic illness (IACI). This episode is part of a special series showcasing how pathobiome and microbiome science is changing our understanding of chronic Lyme and neurodegenerative disease. Learn More Learn about the Alzheimer's Pathobiome Initiative (AlzPI) at AlzPI.org. For Dr. Balin's publications and ongoing research, visit the Philadelphia College of Osteopathic Medicine (PCOM) website. Learn more about the Alzheimer's Pathobiome Initiative (AlzPI) Listen to Tick Boot Camp Podcast episodes, including Episode 406: Pathobiome – An Interview with Nikki Schultek and Episode 101: The Young Gun – An Interview with Alex (Ali) Moresco discussed in this interview.

The Real Truth About Cholesterol, Heart Disease & Cardiovascular Health SUMMARY What if your cholesterol isn't trying to kill you—it's trying to protect you? In this solo deep-dive, Coach Debbie Potts breaks down the outdated cholesterol myths and reveals the root-cause truth behind cardiovascular disease. Drawing from the work of Dave Feldman, Dr. Ben Bikman, Dr. Paul Mason, Ivor Cummins, and Dr. William Davis, Debbie explains why heart disease is an inflammatory, metabolic, and endothelial problem—not a cholesterol problem. Learn which markers truly predict risk, how to interpret your labs beyond LDL, the role of genetics and epigenetics, and what it really takes to reverse plaque and rebuild a resilient metabolism. If you're ready to move beyond fear and finally understand your cardiovascular health through the lens of functional, ancestral, and root-cause medicine, this episode is your roadmap. KEY TAKEAWAYS LDL isn't "bad"—oxidized, inflamed LDL in a damaged arterial wall is. Heart disease = terrain dysfunction: insulin resistance, oxidative stress, mitochondrial damage, and loss of nitric oxide. ApoB + inflammation predict risk far better than total cholesterol. Context matters: High LDL in a low-inflammation, insulin-sensitive body ≠ the same risk as in a high-inflammation body. Saturated fat isn't the enemy; oxidized seed oils and sugar are. You can't out-supplement poor habits. Sleep, stress regulation, circadian alignment, and daily movement build vascular resilience. Plaque can stabilize or regress when you heal the root causes. The WHOLESTIC Method™ integrates nutrition, movement, sleep, stress, digestion, hydration, and happiness to rebuild your health from the inside out. TESTS & TOOLS MENTIONED - talk to your provider! ApoB (< 80 mg/dL optimal) LDL-P (< 1,000 nmol/L) Triglyceride : HDL ratio (< 1) hs-CRP (< 0.5 mg/L) Lp(a) (< 30 mg/dL) Fasting Insulin / HOMA-IR (< 5 µIU/mL / < 1.0) Coronary Artery Calcium (CAC) Score (0 = clean) CCTA / Cleerly AI Analysis for plaque composition Carotid IMT, Omega-3 Index, Homocysteine, Vitamin D + K2

You've seen the headlines about new blood tests and treatments for Alzheimer's, Parkinson's, and ALS, but what's the science behind those breakthroughs? In this episode, HudsonAlpha scientists Ben Henderson, PhD, and Bri Rogers, PhD, break down the role of biomarkers and genetics in early detection and treatments of neurodegenerative diseases. Discover how research being conducted today is creating real hope for tomorrow.To go behind the scenes and learn more about this episode, visit “Beyond the Headlines: How Biomarkers and Genetics are Changing Neurodegenerative Disease Research.” If you prefer to watch your podcasts, head over to our Youtube channel. Thanks for listening! We're now on YouTube- follow us here. To receive episode updates and bonus material, subscribe to our mailing list here.

Rare diseases do not receive enough attention for the impact they have on patients and their families. This is what AlphaRose's founder and CEO Casey McPherson learned after his daughter was diagnosed with a rare condition. In a conversation with host Ari Berman, McPherson shares how he switched from music to founding his own pharmaceutical company, what technologies AlphaRose is developing, and how his company is creating environments that allow innovation and iteration. He also shares his thoughts on embracing failure in order to make progress and emphasizes holding compassion and understanding for the patients and families that are impacted by rare diseases—because you never know what it's like until it happens to you. Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders.

Have you ever heard of a biobank? Well, this morning, we find out exactly what a biobank is and why they form such an important part of disease research. Biobank Ireland is a trust dedicated to expanding a network of biobanks across Ireland with a specific focus on cancer research. Professor Seán Hynes, Professor in Pathology and Consultant Histopathologist at University Hospital Galway joined Pat Kenny on the show this morning.

A Gluten Free Podcast Episode 197I've had many coeliac disease researchers on this show to share their latest research and findings. Today I want to collate all the exciting coeliac disease research around the world I'm watching right now. I hope you enjoy listening and please get in touch if you learn more developments in the research I talk about during this episode or you know of others that are worth talking about. What we'll chat about: * Reflecting on last my episode with the new Director for the Center for Celiac Disease Research and Treatment, Dr Maureen Leonard * Dr Jason Tye Din & Olivia Moscatelli from WEHI with their Interleukin 2 diagnostic breakthrough allowing patients to avoid the need to consume gluten while testing for coeliac disease accurately * Dr Maureen Leonard's work on the Celiac Disease Genomic Environmental and Metabolomic Study * How the CDGEMM study with help us understand how and why coeliac disease is activating in children * Italy passing a law to screen their population for coeliac disease and Type 1 diabetes in ages 1-17 * The importance of researching the mental health impacts of coeliac disease * Potential therapeutic for Coeliac Disease from Topas Therapeutics (TPM502) * Gluten Threshold study at Wesley Research Institute  * Hookworms and parasite study for coeliac disease treatmentLinks Interleukin Diagnostic tool blog postEpisode with Dr Maureen Leonard Celiac Disease Genomic Environmental, Microbiome and Metabolomic Study Italy's paediatric population screening for coeliac disease and Type 1 diabetes Coeliac Disease research in the UK TPM 502 Gluten Threshold Study Are you looking for a low cost business, that is easy to run and has a high return on investment? OMG! Decadent Donuts wants you! Join this creative, inclusive and rapidly expanding business today. Apply here: https://omgdecadentdonuts.com/opportunity/ Thanks to our sponsor Happy Tummies! Happy Tummies is a one-stop-shop for allergen-friendly and gluten free products and also stocking their very own brand - Free From Family Co. Click here to have our discount code GFFAMILY automatically applied & save 10% off Free From Family Co products! Celiac Cruise - a 100% gluten free vacation cruise is setting sail on two Australian cruises in 2026: one to the South Pacific and the other to New Zealand. There'll of course be awesome 100% gluten free food onboard, heaps of fun stuff to do, educational talks and a community of people who understand each other. Buy your tickets here & see ya onboard gluten free fam!

In this conversation, Wendy Chung discusses the evolution of understanding genetic conditions, particularly in relation to autism, and the role of Simons Searchlight in patient advocacy. She emphasizes the importance of community support, global inclusion, and the hope for future therapies. The conversation highlights the significance of family connections and the collective effort in advancing research and treatment options for neurodevelopmental disorders.takeaways The understanding of autism has evolved significantly over the years. Community support is crucial for families dealing with genetic conditions. Simon's Searchlight aims to leverage collective knowledge for better outcomes. Language equity is essential for global participation in research. The importance of early detection and intervention cannot be overstated. Families play a vital role in providing feedback for research. The future of treatments looks promising with ongoing research. Building a supportive community can lead to better advocacy for children. The collaboration among researchers worldwide enhances the potential for breakthroughs. Celebrating milestones like 15 years of Simons Searchlight fosters hope and motivation

2025-08-22 Hosts Craig Lipset and Jane Myles hosted a conversation with Alpa Kushillani, VP of Customer Success & Delivery with Gooseberry Research and a rare disease advocate. Alpa shares her family's journey with Duchenne muscular dystrophy and how those experiences inspired her to create new solutions for patient-centered research.We explore the realities of clinical trial participation for rare disease families—from challenges in home healthcare and nurse training to the promise of digital health tools and decentralized approaches. Alpa highlights how Gooseberry Research is working to improve trial accessibility through specialized nurse training, stronger site communication, and partnerships with technology providers.The episode also touches on trial design hurdles, the need for meaningful endpoints, and the future of decentralized clinical trials. Episode Resources:DCT Market TrendResearch About a Novel, Home-Based Assessment for Duchenne Muscular DystrophyYou can join TGIF-DTRA Sessions live on LinkedIn Live on Friday's at 12:00 PM ET by checking out our LinkedIn. Follow the Decentralized Trials & Research Alliance (DTRA) on LinkedIn and X. Learn more about Membership options and our work at www.dtra.org.

In this special episode celebrating 80 years of QIMR Berghofer, one of the Institute's longest-serving scientists about his early days in biochemistry, the mentors who shaped him, and the world-first research that's changing lives. It's funny, heartfelt, and full of science that hits close to home. 

AiArthritis is bringing you along for the journey as part of our Go With Us! Program, this time straight from the EULAR 2025 in Barcelona. In this episode, we're spotlighting key research updates that matter most to patients living with AiArthritis diseases. Our 'co hosts, Leila, Tiffany, Deb, and Eileen, are on the ground at EULAR, reporting back with fresh insights into patient-prioritized topics. You'll hear how nutrition and microbiome research is shifting how we understand inflammation and autoimmune risk, why CAR T-cell therapy is creating buzz as a potential path to long-term remission, and what new research is saying about enthesitis in spondyloarthritis. Plus, learn more about the debate on the pros and cons of cannabis use for chronic pain management. This episode brings the conference experience straight to you with a focus on what it all means for real patients.   Donate to Support the Show: www.aiarthritis.org/donate   Episode Highlights: Insights from new research linking diet and gut health to autoimmune activity What CAR T-cell therapy could mean for the future of treatment A deeper look at enthesitis and how it's being understood in spondyloarthritis How the medical community is reevaluating the use of cannabis in treatment plans.   Links & Resources Go With Us! To EULAR 2025 YouTube Playlist: https://www.youtube.com/playlist?list=PLZW5ZyvNnYl3wsrI7usV495JH2OMfUdzN Have questions about this episode or topics you want to hear us bring to the table? Email us at podcast@aiarthritis.org  Follow AiArthritis on all social media platforms @IFAiArthritis Sign up for our Monthly AiArthritis Voices 360 Talk Show newsletter! HERE   Connect with our Co Hosts:   Leila is the Health Education Manager at the International Foundation for AiArthritis. She is a person living with Lupus and Sjögren's disease. She is passionate about inclusion and diversity in health education and meeting individuals where they are at in order to learn in a way that resonates with them.   Eileen Davidson is a rheumatoid arthritis patient advocate from Vancouver Canada. She volunteers with the Arthritis Research Canada patient advisory board and the Canadian Institute of Health Research - Institute of Musculoskeletal Health and Arthritis patient engagement research ambassador, among others. When not advocating she is writing about her experience with arthritis through Creaky Joints, Healthline, Chronic Eileen or can be found being a mom to her son Jacob.   Tiffany Westrich-Robertson is the CEO at AiArthritis (International Foundation for Autoimmune & Autoinflammatory Arthritis) and uses her professional expertise in mind-mapping and problem solving to help others, like her, who live with AiArthritis diseases work in unison to identify and solve unresolved community issues.   Deb Constien is a medically retired Registered Dietitian and a Representative for AiArthritis with Rheumatoid Arthritis. Deb is also on the Advisory Council for WREN- Wisconsin Research Education Network and a Patient Family Advisor- PFA on an International PCORI research study for ACP- Advanced Care Planning.

A Gluten Free Podcast Episode 186This week on the podcast, I'm joined by Associate Professor Kelly Lambert, Academic Program Director for Nutrition and Dietetics at the University of Wollongong in New South Wales. Kelly and I first connected during a panel discussion at the Sydney Gluten Free Expo, where we tackled one of the most talked-about and often frustrating issues in the coeliac and gluten free space – the cost of gluten free food.With the rising cost of living, the financial burden of maintaining a gluten free diet has only become more difficult for those of us with coeliac disease. Kelly has spent years studying this issue and shares some brand new research findings in this episode, including how her team conducted the studies and what the results reveal about the state of gluten free food affordability in Australia.

In this Mission Matters Milken Conference Series episode, ⁠Adam Torres⁠ interviews ⁠Ana Rita Moreira⁠, Executive Director of v-ATPase Alliance. Ana Rita shares how a rare diagnosis for her son led her to found a nonprofit that collects critical data to drive research for ultra-rare genetic conditions. Through grassroots collaboration and strategic advocacy, her organization is filling the scientific gap where few others will. Follow Adam on Instagram at ⁠https://www.instagram.com/askadamtorres/⁠ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: ⁠https://missionmatters.lpages.co/podcastguest/⁠ Visit our website: ⁠https://missionmatters.com/⁠ More FREE content from Mission Matters here: ⁠https://linktr.ee/missionmattersmedia⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this Mission Matters Milken Conference Series episode, Adam Torres interviews Ana Rita Moreira, Executive Director of v-ATPase Alliance. Ana Rita shares how a rare diagnosis for her son led her to found a nonprofit that collects critical data to drive research for ultra-rare genetic conditions. Through grassroots collaboration and strategic advocacy, her organization is filling the scientific gap where few others will. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

Investigative journalist Charles Piller explains the remarkable story of fraud he has uncovered in Alzheimer's Disease research, which he discusses in a new book: Doctored: Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimer's. Charles argues the result of this is that Alzheimer's research and treatment has been set by years - if not decades. He goes on to discusse the trial data on which several Alzheimer's drugs, including Aducanumab, Lecanemab and Donanemab, were approved. Charles says the data is unconvincing and  the side effects – including brain swelling and bleeding -  concerning. Doctored: Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimer's by Charles Piller is published by Icon Books. Charles Piller is an investigative journalist who works for the journal Science. His work has also been published in a number of other publications including The New York Times and the Los Angeles Times. Charles has won a number of journalism awards for his work and is also the author of the books Gene Wars and The Fail-Safe Society. The host of the podcast, Liz Tucker is an award winning medical journalist and former BBC producer and director.  You can follow Liz on Twitter at https://twitter.com/lizctucker and read her Substack newsletter about the podcast at https://liztucker.substack.com If you would like to support this podcast you can do so via Patreon at https://www.patreon.com/WhatYourGPDoesntTellYou or via PayPal at https://www.whatyourgpdoesnttellyou.com/support/ What Your GP Doesn't Tell You has been selected by Feedspot as one of the top 15 UK Medical Podcasts https://blog.feedspot.com/uk_medical_podcasts/

A Gluten Free Podcast Episode 184 In this episode of A Gluten Free Podcast, I'm joined by Dr. Andrew Williams, Principal Scientist at Westmead Children's Hospital in Sydney, Australia. Dr. Williams has spent decades researching coeliac disease and the complex immunological processes behind it. We explore how coeliac disease research has evolved, what still needs to change, and how early diagnosis in children could significantly improve health outcomes across Australia and globally.We dive into the inspiration behind Dr. Williams' career in immunological research, his earliest experiences working with children diagnosed with coeliac disease, and what initially drew his attention to this autoimmune condition. With so many people still undiagnosed, we talk about how Australia compares to other countries like Italy, where screening children for coeliac disease and Type 1 diabetes is already underway.We also discuss promising innovations like the Novoleukin blood test—a tool being developed to detect coeliac disease even in people who are already on a gluten-free diet. This episode offers a hopeful and practical look into how coeliac disease awareness, testing methods, and healthcare systems could shift for the better—if we focus our efforts in the right places.What We Cover:How Dr. Andrew Williams became involved in coeliac disease researchWhat we knew (and didn't know) about coeliac disease when he began his careerMajor milestones in coeliac disease research over the past few decadesReal-life stories from the clinic that shaped his perspectiveThe critical need for early diagnosis in children with coeliac diseaseWhy so many Australians remain undiagnosed and what needs to changeHow other countries like Italy are taking proactive steps to improve coeliac screeningThe future of coeliac disease testing, including the upcoming Novoleukin diagnostic toolWhat parents of children with coeliac disease need to knowHow one powerful conversation reminded him why this work matters

Broadcast from KSQD, Santa Cruz on 5-30-2024 and 5-29-2925: Cognitive errors in medicine dismissing unusual presentations as psychological A case of Pediatric Autoimmune Neuropsychiatric disorders Associated with Streptococcal Infections (PANDAS) Anti-NMDA receptor encephalitis causing psychiatric symptoms Failures of genetic research to identify causes Need for integrating neurology and psychiatry; Importance of testing for antibodies and using MRI scans Detailed explanation of immune tolerance, peripheral tolerance, and the phenomenon of molecular mimicry in diseases like multiple sclerosis and celiac disease Importance of addressing root causes rather than just symptoms Historical context and current advancements in treating autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis using reprogrammed immune cells and iron oxide nanoparticles Explanation of how the liver filters blood and helps establish immune tolerance by processing cellular debris and antigens Advances in engineering regulatory T cells to target specific disease sites and calm inflammatory responses Exploration of new diagnostic tools and the potential of AI in understanding complex psychiatric conditions Detection of colds and other diseases by analysis of voice frequency patterns

Broadcast from KSQD, Santa Cruz on 5-30-2024 and 5-29-2925: Cognitive errors in medicine dismissing unusual presentations as psychological A case of Pediatric Autoimmune Neuropsychiatric disorders Associated with Streptococcal Infections (PANDAS) Anti-NMDA receptor encephalitis causing psychiatric symptoms Failures of genetic research to identify causes Need for integrating neurology and psychiatry; Importance of testing for antibodies and using MRI scans Detailed explanation of immune tolerance, peripheral tolerance, and the phenomenon of molecular mimicry in diseases like multiple sclerosis and celiac disease Importance of addressing root causes rather than just symptoms Historical context and current advancements in treating autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis using reprogrammed immune cells and iron oxide nanoparticles Explanation of how the liver filters blood and helps establish immune tolerance by processing cellular debris and antigens Advances in engineering regulatory T cells to target specific disease sites and calm inflammatory responses Exploration of new diagnostic tools and the potential of AI in understanding complex psychiatric conditions Detection of colds and other diseases by analysis of voice frequency patterns

In this episode of The Clinical Research Coach, host Leanne Woehlke sits down with trailblazer Nasha Fitter—tech entrepreneur, rare disease advocate, and co-founder of both the FOXG1 Research Foundation and Citizen Health.After Nasha's daughter was diagnosed with FOXG1 syndrome, an ultra-rare neurological disorder, her world shifted. Instead of accepting the limitations of the current research landscape, she took action- building a foundation, galvanizing the scientific community, and redefining what's possible for families facing rare disease.What began as a grassroots foundation now drives innovative drug development, redefines data collection, and challenges the status quo in drug development.In this conversation, Nasha shares:How a small, determined parent community raised $10M and launched a gene therapy programWhy traditional research models fail rare disease patients—and how to fix themThe power of patient-owned data and how platforms like Citizen Health are transforming access and insightsHow to build empathy for families navigating special needsWhat pharma gets wrong (and right) in working with advocacy groupsHer vision for a precision medicine future—starting with ultra-rareThis is a story about courage, creativity, and a more inclusive, patient-driven future of medicine. Nasha's bold vision and action oriented approach will leave you inspired and hopeful.To Find Out More:Nasha Fitterhttps://www.linkedin.com/in/nashafitter/FOXG1 Research Foundation: https://www.foxg1research.org/Citizen Health:https://www.citizen.health/

This program is supported by educational grants from Amicus Therapeutics, Inc. and Chiesi USA Inc.Fabry disease is an inherited lysosomal storage disease caused by mutations in the GLA gene, disrupting the function of the enzyme, α-galactosidase. This results in the accumulation of globotriaosylceramide (GL-3) and its deacylated form, globotriaosylsphingosine (lyso-GL-3), leading to progressive disruption of multiple organ systems. There are currently three treatment options available for Fabry disease, including two enzyme replacement therapies, agalsidase beta and pegunigalsidase alfa, and a chaperone therapy, migalastat. There are also other treatments in development (e.g., gene therapy, other enzyme replacement therapies) and some that are available in other countries (e.g., agalsidase alfa). Due to the small patient population and variability in Fabry disease severity, it is challenging to develop properly powered, placebo-controlled clinical trials. As such, data shared at conferences like WORLDSymposium 2025 are crucial for guiding best practices in this disease area. This program, led by Dr. Eric Wallace, provides a summary of clinically relevant data presented at WORLDSymposium 2025 that can enhance the care of patients with Fabry disease.  Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology, nephrology, cardiology, gastroenterology, ophthalmology, and dermatology. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to: Describe the latest research being presented to better manage individuals with Fabry disease and its clinical relevance.Eric Wallace, MDProfessor of MedicineDepartment of NephrologyUniversity of Alabama Medical SchoolDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Wallace discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: Sanofi-Genzyme, Chiesi, Kyowa Kirin, Sangamo, NateraGrant/Research Support: Sanofi-Genzyme, Chiesi, Uniqure, Idorsia, Amicus Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.Hardware/Software RequirementsWindows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

On this episode, Tania Simoncelli (Vice President, Translational Impact and Engagement, Chan Zuckerberg Initiative) and Nasha Fitter (Co-founder & CBO, Citizen Health and Co-founder & CEO, FOXG1 Research Foundation) join forces to discuss how rare disease patient advocacy has transformed over time and how the biopharmaceutical industry should adapt to better meet the needs of today's patients. They dive deeper into the evolution of rare disease patient advocacy groups, why industry must move beyond the hyperfocus on “blockbuster drugs” to make progress in rare disease research, and how advancements in rare disease treatments can benefit the clinical research ecosystem for all.

When Hannah Lowe's son was diagnosed with a rare disease, she turned fear into fuel and founded the L-CMD Research Foundation and led a successful $2M peer-to-peer fundraising campaign from scratch. In this episode, she shares her journey, the unique challenges of leading rare disease research, and how personal storytelling and community-driven fundraising can accelerate impact against all odds.

A Gluten Free PodcastEpisode 176On today's episode I chat with Associate Professor Dr Bob Anderson — a world-renowned gastroenterologist, immunologist and trailblazer in coeliac disease research. From his foundational work at the Walter and Eliza Hall Institute (WEHI) to creating Nexvax2, leading Novoviah Pharmaceuticals, and becoming President of the International Society for the Study of Coeliac Disease (ISSCD), Bob has shaped the coeliac research landscape as we know it.We discuss how his career began, what he's most excited about in current research, and what's ahead for coeliac disease globally — including a look at ICDS 2026 in Melbourne.What We Cover

Having a kidney stone is painful. But, although they're relatively common, they're also quite treatable. Plus learn about a collaborative research team commited to amplifying the voice of kidney stone disease patients. Discover Stepping Stones: Advancing Kidney Stone Disease Research…inside this edition of CTSI Discovery Radio!

A Gluten Free Podcast Episode 174In today's episode I'm joined by Olivia Moscatelli, a PhD student and scientist researching coeliac disease at the Walter and Eliza Hall Institute (WEHI) in Melbourne. Olivia works alongside Associate Professor Jason Tye-Din, one of the world leading experts in coeliac disease research. Not only is she making pivotal contributions to the field, but she also brings a unique and deeply personal perspective—because she lives with coeliac disease herself.We'll dive into Olivia's diagnosis story, what led her into the world of scientific research, and the groundbreaking studies she's currently working on that could transform the way coeliac disease is diagnosed and treated in the future.What we'll cover: 

Episode 69 - Updates in Pleural Disease Research by AABIP

In this episode, we explore the forefront of rare disease research with Professor Matthew Wood, the Director and Chief Scientific Officer at the Oxford-Harrington Rare Disease Centre (OHC). Professor Wood shares his inspiring journey from his early studies in Cape Town to his impactful career at Oxford University. Learn about the innovative initiatives at OHC and their ambitious plan to bring 40 drugs into clinical trials within the next decade. This episode provides valuable insights into the challenges and opportunities in rare disease treatment, presenting a hopeful vision for rapid diagnosis and effective therapies.

We discuss proposed cuts to federal science research funding with Dr. Stanley Perlman, a professor of immunology at the University of Iowa and a world authority on coronaviruses.

Have new breakthroughs been made in treating Parkinson's Disease? Through new therapeutic techniques, promising results have been shown. Listen up to learn: Early parkinsonian symptoms The targets of current research The function of L-Dopa Dr. Anumantha Kanthasamy, the Director of the Center for Brain Science, shares his research and work developing new therapies and detection methods for Parkinson's Disease. Parkinson's Disease and other neurodegenerative diseases have long plagued folks around the globe. Unfortunately, despite the prevalence of these conditions, there has been little progress in treating or reversing the associated symptoms. One of the most promising sites of progress in treating such diseases has been the gut biome. Since the gut biome is one of the most significant influences on the rest of the body, learning how to influence it can help us better regulate the brain. Visit https://vet.uga.edu/person/anumantha-kanthasamy/ to learn more. Episode also available on Apple Podcasts: http://apple.co/30PvU9C Boost Your Brainpower with 15% OFF!  Fuel your mind with BrainSupreme Supplements and unlock your full potential. Get 15% OFF your order now using this exclusive link: brainsupreme.co/discount/findinggenius Hurry—your brain deserves the best!

Dr. Neal Barnard discusses recent findings and a potential breakthrough related to Alzheimer's disease.   He joins Chuck Carroll on The Exam Room Podcast to highlight both the challenges and promising developments in research. The discussion comes as new cases of dementia are expected to double by 2060.   Dr. Barnard is the author of The Power Foods Diet.   Topics discussed:    Microbiome and Antivirals: New evidence suggests that the brain's microbiome may play a role in Alzheimer's. Antiviral medications, similar to those used for cold sores, could reduce the risk of developing Alzheimer's by over 90%.     Vaccinations: There is a correlation between receiving certain vaccines and a lower risk of Alzheimer's, although vaccines can have risks.     Dietary impact: A Mediterranean diet, which avoids saturated fats, has been linked to a reduced risk of Alzheimer's.     Exercise: Regular brisk walking can help regenerate the hippocampus, which is crucial for memory.     Antioxidants: Antioxidants, particularly vitamin E, may also play a role in reducing Alzheimer's risk.     Omega-3 fatty acids: While omega-3 supplements are popular, there are concerns about their link to prostate cancer, suggesting a focus on natural sources instead.     Berries and anthocyanins: Foods rich in anthocyanins, like berries, are beneficial for brain health.   This episode is sponsored by The Gregory J. Reiter Memorial Fund, which supports organizations like the Physicians Committee that carry on Greg's passion and love for animals through rescue efforts, veganism, and wildlife conservation.   — — BOOKS — — The Power Foods Diet: https://amzn.to/3GmCxUj — — EVENTS — — Dr. Bulsiewicz and Chuck Live Show Where: Dr. Barnard's Bon Voyage Bash in Miami Date: March 7, 2025 Tickets: https://www.pcrm.org/events/bon-voyage-party-2025 — — SHOW LINKS — — Gregory J. Reiter Memorial Fund https://gregoryreiterfund.org — — — Food For Life Instructor Applications http://www.ffltraining.org — — BECOME AN EXAM ROOM VIP — — Sign up: https://www.pcrm.org/examroomvip — — THIS IS US — — The Exam Room Podcast Instagram: https://www.instagram.com/theexamroompodcast — — — Dr. Neal Barnard Instagram: https://www.instagram.com/drnealbarnard Facebook: http://bit.ly/DrBarnardFB X: https://www.twitter.com/drnealbarnard — — — Chuck Carroll Instagram: https://www.instagram.com/ChuckCarrollWLC Facebook: http://wghtloss.cc/ChuckFacebook X: https://www.twitter.com/ChuckCarrollWLC — — — Physicians Committee Instagram: https://www.instagram.com/physicianscommittee Facebook: https://www.facebook.com/PCRM.org X: https://www.twitter.com/pcrm YouTube: https://www.youtube.com/user/PCRM — — SUBSCRIBE & SHARE — — 5-Star Success: Share Your Story Apple: https://apple.co/2JXBkpy​​ Spotify: https://spoti.fi/2pMLoY3 Please subscribe and give the show a 5-star rating on Apple Podcasts, Spotify, or many other podcast providers. Don't forget to share it with a friend for inspiration!

Show Notes: Transforming Pediatric Rare Disease Research with Dr. Ramin Eskandari In this episode, I'm joined by Dr. Ramin Eskandari, a pediatric neurosurgeon at MUSC who is revolutionizing rare disease research through his innovative work with biorepositories. Dr. Eskandari shares how his dedication to helping children and families has driven him to create a system that collects and preserves valuable CNS samples—residual materials that would otherwise be discarded. We discuss the incredible impact of these efforts on the future of rare disease therapeutics and how families can play an active role in advancing research. Highlights: Dr. Eskandari's Path to Pediatric Neurosurgery The Inspiration Behind the Biorepository Project What Are Biorepositories and Why They Matter Advocating for Residual Sample Collection Overcoming Challenges in Setting Up a Biorepository Data Sharing and Expanding Access Scaling This Initiative to Other Institutions Links: Combined Brain The Medical University of South Carolina

Sometimes, you need to go the extra mile to make a point—like buying every medicine at CVS to show regulators that medicine can, and often does, have flavor. Sensible regulations should be rooted in logic, not outdated prohibition fears or baseless stigmas. If cannabis is legalized, it should be treated like any other industry, not one plagued by fear of being a shadowy boogeyman.This week, we sit down with Wendy Bronfein to dive into:Key Differences Between Maryland and Missouri's Cannabis MarketsEmerging Marketing Trends and Customer-Focused StrategiesInnovative Crohn's Disease Research and Product Development...and so much more. Chapters:Introduction and Background (00:00:00) - Brian and Kellen introduce their guest Wendy Bronfein, co-founder of Cura Wellness. Wendy shares her background in the television industry and how she transitioned into the cannabis space.Early Days of Maryland Cannabis (00:01:15) - Wendy discusses how her family became involved in the Maryland medical cannabis market, including their trip to Colorado and the process of applying for a license in 2015.Launching Curio Wellness (00:02:47) - The company won a license, built their facility, and became operational in 2017, shipping to licensed dispensaries in December of that year.Transition to Adult Use (00:03:07) - Maryland transitioned from medical to adult-use cannabis in July, with Wendy explaining the regulatory changes and market dynamics.Product Innovation and Research (00:33:59) - Curio Wellness discusses their approach to product development, including specialized products for sleep, mood, and potential medical treatments like a Crohn's disease tablet.Marketing Challenges and Regulations (00:25:16) - Wendy explains the marketing restrictions in Maryland compared to Missouri, highlighting the challenges of advertising in the cannabis industry.Personal Insights and Closing (00:42:33) - The interview concludes with personal questions about Wendy's dream smoking session, her views on branding, and her favorite ice cream. Guest Linkshttps://curiowellness.com/https://x.com/curiowellnesshttps://www.instagram.com/curiowellnessbrand/https://www.linkedin.com/company/curio-wellness/https://www.youtube.com/channel/UCeT6Sut8Wsi4Xr_o9uq0edQhttps://www.linkedin.com/in/wbronfein/Our LinksBryan Fields on Twitter Kellan Finney on Twitter The Dime on Twitter At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcast The Dime has a New Website. Shhhh its not finished. The Dime is a top 50 Cannabis Podcast Sign up for our playbook here:

 Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers published by Masliah appear to contain manipulated images.  In this week's episode of “The Top Line,” Fierce Biotech's Darren Incorvaia dives into this issue with Matthew Schrag, M.D., Ph.D., a neuroscientist who contributed to the dossier outlining Masliah's misconduct. To learn more about the topics in this episode:   NIH neuroscience leader committed research misconduct, agency investigation findsSee omnystudio.com/listener for privacy information.

In this month's episode, Roberto and Martha chat with Dr. Paula Desplats, an associate professor at UCSD who is currently researching the role of circadian alterations that trigger neuronal death in Alzheimer's disease. Paula discusses the cutting-edge research happening in San Diego and ways for caregivers and their loved ones to get involved in research. Keywords: alzheimer's disease research, brain research, Parkinson's research, treatment, cure

Kidney Week 2024 on the go. Gentzon Hall, MD, PhD, FASN, Matthias Kretzler, MD, and Heather Reich, MD, PhD, discuss progress in glomerular disease research, emerging trends, and clinical challenges.

Dr. Brad White of Kansas State University and Director of the Beef Cattle Insitute talks about his team's research into Bovine respiratory disease, or Shipping Fever. Bovine respiratory disease costs ranchers in the United States about $900 million annually due to animal death, reduced feed efficiency and treatment costs. The research represents the most comprehensive assessment of risk factors and pathological characteristics of late day pulmonary disease ever reported, generating valuable results that will help ranchers and veterinarians improve animal welfare, mitigate the negative impacts of this disease while promoting antimicrobial stewardship.

Broadcast from KSQD, Santa Cruz on 5-30-2024 and 9-05-2024: Cognitive errors in medicine dismissing unusual presentations as psychological A case of Pediatric Autoimmune Neuropsychiatric disorders Associated with Streptococcal Infections (PANDAS) Anti-NMDA receptor encephalitis causing psychiatric symptoms Failures of genetic research to identify causes Need for integrating neurology and psychiatry; Importance of testing for antibodies and using MRI scans Detailed explanation of immune tolerance, peripheral tolerance, and the phenomenon of molecular mimicry in diseases like multiple sclerosis and celiac disease Importance of addressing root causes rather than just symptoms Historical context and current advancements in treating autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis using reprogrammed immune cells and iron oxide nanoparticles Explanation of how the liver filters blood and helps establish immune tolerance by processing cellular debris and antigens Advances in engineering regulatory T cells to target specific disease sites and calm inflammatory responses Exploration of new diagnostic tools and the potential of AI in understanding complex psychiatric conditions Detection of colds and other diseases by analysis of voice frequency patterns

Broadcast from KSQD, Santa Cruz on 5-30-2024 and 9-05-2024: Cognitive errors in medicine dismissing unusual presentations as psychological A case of Pediatric Autoimmune Neuropsychiatric disorders Associated with Streptococcal Infections (PANDAS) Anti-NMDA receptor encephalitis causing psychiatric symptoms Failures of genetic research to identify causes Need for integrating neurology and psychiatry; Importance of testing for antibodies and using MRI scans Detailed explanation of immune tolerance, peripheral tolerance, and the phenomenon of molecular mimicry in diseases like multiple sclerosis and celiac disease Importance of addressing root causes rather than just symptoms Historical context and current advancements in treating autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis using reprogrammed immune cells and iron oxide nanoparticles Explanation of how the liver filters blood and helps establish immune tolerance by processing cellular debris and antigens Advances in engineering regulatory T cells to target specific disease sites and calm inflammatory responses Exploration of new diagnostic tools and the potential of AI in understanding complex psychiatric conditions Detection of colds and other diseases by analysis of voice frequency patterns

In 2010, our guest, Rob Long, was on the cusp of an NFL career after being a star punter at Syracuse University. But that bright future was sidelined when Rob was diagnosed with a rare and aggressive brain tumor just five days after his final college game. Fortunately, emergency surgery and treatment gave him a second chance. As you'll learn in this fascinating episode of Raise the Line, a new purpose took the place of his NFL dreams and today he's the executive director of Uplifting Athletes, a nonprofit using sports to raise awareness and resources for rare diseases. One signature program developed under his leadership is the Young Investigator Draft held annually since 2018 at the home stadium of the Philadelphia Eagles. “Our program is modeled after the NFL draft, but instead of drafting the top athletes in the country, we draft and fund the next generation of rare disease researchers,” Long tells host Lindsey Smith. So far, Uplifting Athletes has provided fifty researchers with over one million dollars in grants through this approach. Tune in to learn about other innovative work that has connected hundreds of rare disease patients with professional athletes and provided opportunities for researchers to attend patient & family conferences as our Year of the Zebra focus on rare disorders continues. Mentioned in this episode: Uplifting Athletes

Welcome! Today, we're exploring the key milestones in Lyme disease research and treatment.I had a 57-year-old patient who remained chronically ill after being diagnosed and treated for Lyme disease. He didn't realize that a persistent tick-borne infection could explain his chronic illness. He was treated with a combination of azithromycin and atovaquone for the persistent infection, and today, he is doing well.He was surprised that, despite the milestones in Lyme disease research, he wasn't aware that a persistent infection could lead to his chronic illness. So, let's take a closer look at these milestones.1. 1977: Discovery of Lyme DiseaseOur story begins in 1977 in Lyme, Connecticut. A cluster of children and adults were diagnosed with what was initially thought to be juvenile rheumatoid arthritis. This event marked the identification of Lyme disease as a distinct illness and the start of modern Lyme disease awareness."2. 1982: Discovery of the Bacterium Responsible for Lyme DiseaseIn 1982, Dr. Willy Burgdorfer identified Borrelia burgdorferi, the bacterium responsible for Lyme disease. This discovery was a major milestone, enabling more precise identification and treatment of the disease. 3. 1990: Recognition of Chronic Lyme DiseaseBy 1990, chronic Lyme disease, with its long-term and persistent symptoms, was officially recognized. This led to more comprehensive treatment protocols and increased awareness of the disease's chronic nature.4. 1995: Discovery of Babesia microtiIn 1995, Babesia microti was identified as a co-infection transmitted by the same ticks that carry Lyme disease. This highlighted the complexity of tick-borne illnesses and the need for integrated treatment approaches. 5. 2000: Publication of IDSA and ILADS GuidelinesThe year 2000 saw the publication of treatment guidelines by both the Infectious Disease Society of America (IDSA) and the International Lyme and Associated Diseases Society (ILADS). These guidelines showcased different approaches to treating Lyme disease, marking another significant milestone. 6. Ongoing Research and Future Milestones Research is ongoing, and we look forward to future milestones that could lead to breakthroughs in diagnosis and treatment. Studies on biofilms, persisters, and tick-borne co-infections may enable doctors to develop treatment plans that significantly improve patient outcomes.ConclusionUnderstanding these milestones helps us appreciate the progress made in the fight against Lyme disease. With continued research and dedication, we move closer to effective management and potential cures. Thank you for watching, and stay tuned for more insights on Lyme disease." 

Interview with Sharon Brangman, MD, Upstate geriatrics chief

What to expect at Blackhat/DEFCON, Identifying Explosives, OpenAI's new models, Llama 4 Timeline, and more…  ➡ Check out Vanta and get $1000 off:vanta.com/unsupervised Subscribe to the newsletter at: https://danielmiessler.com/subscribe Join the UL community at:https://danielmiessler.com/upgrade Follow on X:https://twitter.com/danielmiessler Follow on LinkedIn:https://www.linkedin.com/in/danielmiessler See you in the next one!Discussed in this episode:Intro (00:00:00)OSINT and the Pizza Index (00:01:08)Agent Framework Development (00:02:12)State of Cybersecurity (00:04:08)Critical Security Vulnerabilities (00:05:27)Ransomware Trends (00:06:25)Data Breach Costs (00:07:29)AI Developments (00:08:40)California AI Regulation (00:09:42)OpenAI's GPT-4 Launch (00:11:01)Tech Company Updates (00:12:03)Shifts in Workforce Dynamics (00:13:07)Prisoner Swap News (00:17:06)Shark AI Model (00:18:03)Dementia Prevention Insights (00:19:03)Genetics of Self-Control (00:20:12)Name and Appearance Study (00:20:12)Alzheimer's Disease Research (00:20:12)Dungeons and Dragons Rulebooks (00:20:12)Novelists Writing Bug Reports (00:21:22)Recent UBI Study Analysis (00:21:22)Free-Range Kids Initiative (00:21:22)Discovery Farm Bot (00:22:13)Super Memory AI (00:22:13)Avi Shipman's AI Pendant (00:22:13)Installing Fabric (00:22:13)Fleet Open Source Tool (00:22:13)SOC2 Policy Templates (00:22:13)Clutch Security Platform (00:22:13)Black Hat Reminder (00:23:48)Aphorism of the Week (00:23:48)Become a Member: https://danielmiessler.com/upgradeSee omnystudio.com/listener for privacy information.

Join us as we welcome back Dr. Veera Rajagopal, a discovery scientist at Regeneron with an interest in human genetics and drug target discovery in neuroscience and psychiatry. If you're a regular listener of The Genetics Podcast, you are likely familiar with Dr. Veera's annual round-up episodes. This year, we are excited to announce quarterly episodes with Dr. Veera, where he and Patrick walk you through the latest developments in genetics, drug discovery, and precision medicine throughout the year. This quarter's episode will dive into the discovery of a recurrent de novo mutation in a noncoding region linked to neurodevelopmental disorders, the role of RAB32 in Parkinson's disease (PD), insights into monogenic conditions like systemic lupus erythematosus, and new perspectives on Alzheimer's genetics. Tune in now, and don't forget to check out Veera's substack, GWAS Stories, and his Twitter, @doctorveera.

This week brought more hot temperatures to the US, and wildfires to Canada, but planters continued to roll. Delaney caught up with Dr. Megan Niederwerder, Executive Director of SHIC, to talk about their work at the Swine Health Information Center with a specific focus on foreign animal disease research. This week's headlines include weather, planting progress, the latest Avian Influenza updates, cash rents, and a daily agronomy update with REDSTAR! And be sure to stick around for the very end of the show, when we cover a weekly recap of the markets. Don't forget to hit subscribe! Follow us on social media!

KSQD 05-30-2024: Topics discussed include: Cognitive errors in medicine dismissing unusual presentations as psychological A case of Pediatric Autoimmune Neuropsychiatric disorders Associated with Streptococcal Infections (PANDAS) Anti-NMDA receptor encephalitis causing psychiatric symptoms Failures of genetic research to identify causes Need for integrating neurology and psychiatry; Importance of testing for antibodies and using MRI scans Detailed explanation of immune tolerance, peripheral tolerance, and the phenomenon of molecular mimicry in diseases like multiple sclerosis and celiac disease Importance of addressing root causes rather than just symptoms Historical context and current advancements in treating autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis using reprogrammed immune cells and iron oxide nanoparticles Explanation of how the liver filters blood and helps establish immune tolerance by processing cellular debris and antigens Advances in engineering regulatory T cells to target specific disease sites and calm inflammatory responses Exploration of new diagnostic tools and the potential of AI in understanding complex psychiatric conditions

KSQD 05-30-2024: Topics discussed include: Cognitive errors in medicine dismissing unusual presentations as psychological A case of Pediatric Autoimmune Neuropsychiatric disorders Associated with Streptococcal Infections (PANDAS) Anti-NMDA receptor encephalitis causing psychiatric symptoms Failures of genetic research to identify causes Need for integrating neurology and psychiatry; Importance of testing for antibodies and using MRI scans Detailed explanation of immune tolerance, peripheral tolerance, and the phenomenon of molecular mimicry in diseases like multiple sclerosis and celiac disease Importance of addressing root causes rather than just symptoms Historical context and current advancements in treating autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis using reprogrammed immune cells and iron oxide nanoparticles Explanation of how the liver filters blood and helps establish immune tolerance by processing cellular debris and antigens Advances in engineering regulatory T cells to target specific disease sites and calm inflammatory responses Exploration of new diagnostic tools and the potential of AI in understanding complex psychiatric conditions

Dr. Pierre Vanderhaeghen is a Professor and Principal Investigator at VIB-KU Leuven Center for Brain & Disease Research. His lab studies the mechanisms of cortical development and brain evolution. He talks about species-specific neuronal development, human neuron excitability, and playing in a rock cover band!

ONCE UPON A GENE - EPISODE 214 A Courageous Gift - The Power of Brain and Tissue Donation in Rare Disease Research with Anne Rugari Anne Rugari is an advocating powerhouse, an author of two children's books, a mom, and two of her children have passed away from Krabbe disease. She joins us to share her personal story and also share her knowledge about tissue and organ donation. EPISODE HIGHLIGHTS Can you share how you became part of the rare disease world? In 1986, my second child Nick received a diagnosis of Krabbe disease, or globoid cell leukodystrophy, a terminal disease that took him just after his first birthday. I also had a three year old son who was unaffected and we decided we probably wouldn't have another child with a rare disease if we wanted more children. In 1999, my daughter Gina was born and tested for Krabbe disease, confident the odds were with us. Unfortunately, she tested positive. As a result of an umbilical cord blood transplant she had at three weeks old, she did remarkably well and lived to fifteen years old.  What were your considerations when deciding to donate Gina's brain for research? It's an emotional, practical and religious decision. There are so many factors that play into the decision. For me personally, I wanted to make sure I was making a sound decision morally and spiritually. I felt we weren't going to learn more about the disease unless there were human tissues and samples to study. It was a decision I felt strongly about to help others. There's a source of comfort knowing that the tissues donated are being used to move research forward.  Why is it important to consider and arrange tissue donation in advance? It's emotional and you don't want to be making those decisions at a time when you've lost them. There's also some coordination that needs to be planned, ensuring there's a pathologist available at the hospital for the retrieval. Planning in advance allows you time to coordinate the details, like if passing takes place at home instead of the hospital, and notifying the funeral home so they can coordinate with the pathologist. Getting the logistics organized in advance makes the transition when someone passes away easier. Discuss plans in advance with your care team so they can help with arrangements and support you.  LINKS AND RESOURCES MENTIONED ONCE UPON A GENE - EPISODE 213 - Finding Strength In Every Step https://effieparks.com/podcast/episode-213-finding-strength-in-every-step ONCE UPON A GENE - EPISODE 198 - Advocating with Heart - Striking the Balance Between Medical Insights and Personal Narratives - A Tribute to Valerie Marie with RING14 Co-Founder Yssa Dean DeWoody https://effieparks.com/podcast/episode-198-advocating-with-heart Courageous Parents Network  https://courageousparentsnetwork.org/ Anne Rugari Website https://www.annerugari.com/ Just Like Me!: A Book About A Girl with a Rare Disease https://www.amazon.com/Just-Like-Me-about-Disease/dp/0982218710 Just Like Me Too! https://www.amazon.com/Just-Like-Too-Anne-Rugari/dp/1970063378 CONNECT WITH EFFIE PARKS Website https://effieparks.com/ Twitter https://twitter.com/OnceUponAGene Instagram https://www.instagram.com/onceuponagene.podcast/?hl=en Built Ford Tough Facebook Group https://www.facebook.com/groups/1877643259173346/

We don't have to fear Alzheimer's and cognitive decline like generations before us. Thanks to dedicated researchers and doctors like today's guest, we know why Alzheimer's happens – and how to prevent it.Dr. Dale Bredesen received his undergraduate degree from Caltech and his medical degree from Duke University. In 2013, he returned to UCLA as the director of the Easton Center for Alzheimer's Disease Research. The Bredesen Laboratory studies the basic mechanisms underlying the neurodegenerative process and the translation of the knowledge into effective therapies for Alzheimer's disease. He has published over 230 papers and has written two New York Times bestselling books, The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline, and The End Of Alzheimer's Program. In today's episode, he fills us in on everything he knows about how to protect your brain from this disease, what Alzheimer's is, how we can reverse and prevent it, and blood tests that can indicate our odds of getting it. Dr. Bredesen is a beacon of hope for so many of us and for families that have been affected by this disease. Knowing that we have the tests to catch early signs of cognitive decline and can harness the power of the Bredesen Protocol to fight inflammation through diet and lifestyle changes in our earlier years means that we can end Alzheimer's.We also cover…(00:01:53) Preventing Alzheimer's(00:06:56) The 4 Stages of Alzheimer's(00:16:12) Understanding the Root Cause of Alzheimer's(00:22:40) Alzheimer's Testing 101(00:25:52) Addressing the Glucose Energetic Emergency(00:30:48) The Bredesen Protocol: Diet Recommendations To Prevent Alzheimer's(00:38:36) What Leads to Brain Inflammation & How To Identify It(00:47:12) Why Alzheimer's Is a Women Centric Disease(00:50:22) Best-in-Class Methods for Reducing Brain InflammationThis episode is brought to you by:BWBK Protein Powder | Get $10 off your order with PODCAST10 at bewellbykelly.com.Cozy Earth | Get 35% off site wide when you use the code BEWELL at CozyEarth.com.MasterClass | This holiday season, give one annual membership and get one free at masterclass.com/bewell. Resources:Click here for full show notesRead: The End of Alzheimer's by Dr. Dale BredesenRead: The End of Alzheimer's Program by Dr. Dale BredesenWebsite:

Welcome to this week's episode of Fast. Feast. Repeat. Intermittent Fasting for Life, with Gin Stephens and Sheri Bullock.To make a submission for the podcast, go to fastfeastrepeat.com/submit. We are a community-driven podcast, and we look forward to sharing your questions, success stories, non-scale victories, IF tweaks, motivational quotes (and more!) on each episode of the podcast. Resources used in today's episode: https://www.beautycounter.com/sheribullock https://www.sciencedirect.com/science/article/pii/S1550413123002735?via%3Dihub Go to fastfeastrepeat.com to see Gin's and Sheri's favorite things, and to shop with us. Every purchase you make through links on our website help to support this podcast so we can keep bringing you episodes each week. Are you ready to take your intermittent fasting lifestyle to the next level? There's nothing better than community to help with that. In the Delay, Don't Deny community we all embrace the clean fast, and there's just the right support for you as you live your intermittent fasting lifestyle. Connect with both Gin and Sheri in the community, as well as thousands of other intermittent fasters who are there to support you along your journey. If you're new to intermittent fasting or recommitting to the IF lifestyle, join the 28-Day FAST Start group. After your fast start, join us for support in The 1st Year group. Need tips for long term maintenance? We have a place for that! There are many more useful spaces beyond these, and you can interact in as many as you like.Visit ginstephens.com/community to join us. An annual membership costs just over a dollar a week when you do the math. If you aren't ready to fully commit for a year, join for a month and you can cancel at any time. If you know you'll want to stay forever, we also have a lifetime membership option available. IF is free. You don't need to join our community to fast. But if you're looking for support from a community of like-minded IFers, we are here for you at ginstephens.com/community.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5913143/advertisement